To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with nonsmall- cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas. © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer / Kerr, K. M.; Bubendorf, L.; Edelman, M. J.; Marchetti, A.; Mok, T.; Novello, S.; O'Byrne, K.; Stahel, R.; Peters, S.; Felip, E.; Besse, B.; Vansteenkiste, J.; Eberhardt, W.; Baas, P.; Reck, M.; Syrigos, K.; Paz-Ares, L.; Smit, E. F.; Meldgaard, P.; Adjei, A.; Nicolson, M.; Crino, L.; Schil, P. V.; Senan, S.; Faivre-Finn, C.; Rocco, G.; Veronesi, G.; Douillard, J. -Y.; Lim, E.; Dooms, C.; Weder, W.; De Ruysscher, D.; Le Pechoux, C.; De Leyn, P.; Westeel, V.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 25:9(2014), pp. 1681-1690. [10.1093/annonc/mdu145]
Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer
Veronesi G.;
2014-01-01
Abstract
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with nonsmall- cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas. © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
